Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer

Inclusion Criteria:

1. Age ≥18 years old, gender unlimited;
2. A clear diagnosis of leptomeningeal metastases derived from lung cancer , includingpositive cerebrospinal fluid cytology and/or neuroimaging diagnosis;
3. A clear history of lung cancer, including histopathological diagnosis, or acombination of cytopathology and imaging;
4. Proper organ function (neutrophil count ≥1.5× 109 /L, platelet count ≥100× 109 /L,hemoglobin concentration ≥90g/L, serum transaminase concentration ≤2.5 times the limitof normal value, serum creatinine concentration ≤ 1.5 times the upper limit of normalvalue, proteinuria ≤1+)
5. Dexamethasone ≤2 mg (or equivalent) 7 days before the start of treatment in patientsrequiring long-term use of the hormone
6. Signed the informed consent and was willing to follow the experimental protocol andfollow-up

Exclusion Criteria:

1. Patients with positive driver genes and effective treatment, such as patients withpositive EGFR gene sensitive mutation
2. Severe infections or serious comorbidities, such as hemorrhagic peptic ulcer,intestinal obstruction, heart failure, kidney failure, or poorly controlled diabetes;
3. Be allergic to PD-1 inhibitor and recombinant human endostatin
4. The female patient planned to be pregnant, was pregnant and lactating -